Literature DB >> 27441574

The limited benefit of "product-by-process" claim.

Bao-Chi Chang1, Shyh-Jen Wang2,3.   

Abstract

A product-by-process claim was initially developed when the invention could not otherwise be adequately defined. In the US, a patent applicant can use a product-by-process claim for a new product, no matter whether the product can also be defined by using structure features. However, the applicant mainly bears the burden to establish the novelty between the claimed product and the prior art product. Moreover, in terms of infringement, the very recent CAFC cases indicate that the product must be made by a process recited in the claim to infringe a product-by-process claim. Thus, an assignee almost can not take advantage from product-by-process claims during the patent enforcement by comparing with process claims. From the points of the burden during patent prosecution and confined scope in determining infringement, the benefit of using a product-by-process claim would be very limited.

Keywords:  claim; development; infringement; patent; patentability; product-by-process; viral

Mesh:

Substances:

Year:  2016        PMID: 27441574      PMCID: PMC5084995          DOI: 10.1080/21645515.2016.1185211

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  4 in total

1.  The impact of patent eligibility on biotech patents: A flow chart for determining patent eligibility and an immune therapy case study.

Authors:  Bao-Chi Chang; Shyh-Jen Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Product, product-by-process, process and use. What type of protection is best in Europe?

Authors:  V Vossius; S F De Lacroix; U Dörries
Journal:  Biotechnology (N Y)       Date:  1993-10

3.  Product, process, product-by-process. What type of protection is best for you?

Authors:  J A DeGirolamo; D R Auth
Journal:  Biotechnology (N Y)       Date:  1993-04

4.  Phase-dependent immune evasion of herpesviruses.

Authors:  Tal Vider-Shalit; Vered Fishbain; Shai Raffaeli; Yoram Louzoun
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.